IL-20 Subfamily Biological Effects: Mechanistic Insights and Therapeutic Perspectives in Cancer
International Journal of Molecular Sciences · 29.07.2025 · 26 (15) · 7320
DOI: 10.3390/ijms26157320 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.07.2025. Verfasst von Valentina Maggisano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy. Hauptthemen laut MEDLINE: Neoplasms, Interleukins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research.
Abstract (Originalsprache)
The interleukin-20 (IL-20) cytokine subfamily, a subset of the IL-10 superfamily, includes IL-19, IL-20, IL-22, IL-24, and IL-26. Recently, their involvement in cancer biology has gained attention, particularly due to their impact on the tumor microenvironment (TME). Notably, IL-20 subfamily cytokines can exert both pro-tumorigenic and anti-tumorigenic effects, depending on the context. For example, IL-22 promotes tumor growth by enhancing cancer cell proliferation and protecting against apoptosis, whereas IL-24 demonstrates anti-tumor activity by inducing cancer cell death and inhibiting metastasis. Additionally, these cytokines influence macrophage polarization—an essential factor in the immune landscape of tumors—thereby modulating the inflammatory environment and immune evasion strategies. Understanding the dual role of IL-20 subfamily cytokines within the TME and their interactions with cancer cell hallmarks presents a promising avenue for therapeutic development. Interleukin-20 receptor antagonists are being researched for their role in cancer therapy, since they potentially inhibit tumor growth and progression. This review explores the relationship between IL-20 cytokines and key cancer-related processes, including growth and proliferative advantages, angiogenesis, invasion, metastasis, and TME support. Further research is necessary to unravel the specific mechanisms underlying their contributions to tumor progression and to determine their potential for targeted therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.
- Department of Pharmacy and Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.
- Centro Sanitario, Università della Calabria, 87036 Rende, Italy.
- Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.
ORCID-Profile: Francesca Giordano, Diego Russo, Vincenzo Pezzi, Francesca De Amicis
Förderung
- Italian Ministry of University and Research
Zitieren
APA
Maggisano, V., D'Amico, M., Aquila, S., Giordano, F., Battaglia, A. M., Chimento, A., Biamonte, F., Russo, D., Pezzi, V., Bulotta, S., & De Amicis, F. (2025). IL-20 Subfamily Biological Effects: Mechanistic Insights and Therapeutic Perspectives in Cancer. International Journal of Molecular Sciences, 26(15), 7320. https://doi.org/10.3390/ijms26157320
Vancouver
Maggisano V, D'Amico M, Aquila S, Giordano F, Battaglia AM, Chimento A, et al. IL-20 Subfamily Biological Effects: Mechanistic Insights and Therapeutic Perspectives in Cancer. International Journal of Molecular Sciences. 2025;26(15):7320. doi:10.3390/ijms26157320
BibTeX
@article{Maggisano2025,
author = {Maggisano, Valentina and D'Amico, Maria and Aquila, Saveria and Giordano, Francesca and Battaglia, Anna Martina and Chimento, Adele and Biamonte, Flavia and Russo, Diego and Pezzi, Vincenzo and Bulotta, Stefania and De Amicis, Francesca},
title = {IL-20 Subfamily Biological Effects: Mechanistic Insights and Therapeutic Perspectives in Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {15},
pages = {7320},
doi = {10.3390/ijms26157320}
}
EUVIMED